The cruelest irony in modern medicine: the drugs most likely to save your life in a crisis are the least profitable to make. Since 2017, more antibiotic companies have gone bankrupt than have launched successful products. The pipeline has contracted 35% in five years. The market that should reward companies for solving antimicrobial resistance instead punishes them for trying.
But something is changing. Eight countries and the European Union are now running parallel experiments on how to fix this broken market — each testing a different theory about what went wrong and how to make antibiotic development financially viable again. The UK's subscription model, the world's first fully delinked payment system, begins its expanded phase on April 1, 2026. The EU's transferable exclusivity voucher awaits formal adoption. The US PASTEUR Act sits in Congress for its fourth introduction, still unvoted. Italy has quietly become the second G7 nation to meet its fair share.
This is not a unified strategy. It is a collection of divergent bets, each reflecting different political constraints, economic philosophies, and levels of urgency. The question is whether any of them — alone or together — can outrun the resistance crisis.
The Graveyard That Explains the Urgency
Before understanding the solutions, you need to understand the scale of the failure they're trying to fix.
The pattern is consistent and devastating. Of 12 antibiotic-focused IPOs in the past decade, only five companies remain active. The average share price for anti-infective drug companies has fallen 71% since 2018. The 2026 AMR Benchmark found that pipeline projects among large pharmaceutical companies have declined 35% since 2021, with small biotechs now carrying nearly a quarter of all projects — companies that, as the graveyard shows, are least equipped to survive the market.
The economics are simple and brutal. A new cancer drug averages billions in annual revenue. A new antibiotic averages $46 million. The risk-adjusted net present value of an antibiotic project is roughly $100 million — an order of magnitude below a musculoskeletal drug at $1.15 billion. The drugs the world most urgently needs are the drugs the market least wants to fund.
Three Theories of the Fix
The countries now experimenting with solutions are testing three fundamentally different economic theories about how to repair this market. Each reflects different assumptions about what went wrong and who should pay.
These are not just different payment mechanisms. They embody different answers to the core question: who bears the cost of drugs we hope never to use at scale?
The UK: First to Market, First to Scale
The United Kingdom's Antimicrobial Products Subscription Model is, by any measure, the most advanced delinked pull incentive in the world. It is also the only one that has actually paid money to companies.
The pilot launched in July 2022 with two contracts: cefiderocol (Shionogi) and ceftazidime-avibactam (Pfizer), each receiving up to £10 million per year for ten years, regardless of how many courses NHS hospitals prescribed. The payment was for availability — the insurance value of having these drugs ready when someone develops a pan-resistant Gram-negative infection.
NICE's evaluation found that cefiderocol generated approximately 16,200 QALYs and ceftazidime-avibactam approximately 8,800 QALYs over a 20-year horizon. But the committee recognized something beyond direct clinical benefit: these drugs enable other medical treatments (surgery, chemotherapy, organ transplants) that become impossible when last-resort antibiotics fail. The value of an antibiotic is not just the lives it saves — it is the entire edifice of modern medicine that it keeps standing.
On May 8, 2024, the UK government made the pilot permanent — the world's first. On August 12, 2024, NHS England tendered the expanded procurement: up to £1.9 billion over 16 years, covering England, Scotland, Wales, and Northern Ireland. Annual budget: £100 million. Contracts begin April 1, 2026.
Four Bands, Seventeen Criteria
The expanded model assigns each antimicrobial to one of four value bands, determined by a 17-criteria NICE scoring framework across three weighted categories: relative effectiveness and unmet clinical need (the most heavily weighted), pharmacological benefit, and health system benefit. Activity against WHO priority pathogens accounts for 12.2% of the overall score.
| Band | Classification | Annual Payment (England) | Initial Term |
|---|---|---|---|
| 1 | Breakthrough | £20M | 3 years (extendable to 16) |
| 2 | Critical | £15M | 3 years (extendable to 16) |
| 3 | Priority | £10M | 3 years (extendable to 16) |
| 4 | Important | £5M | 3 years (extendable to 16) |
The Environmental Precedent
Buried in the tender requirements is something unprecedented: every manufacturer bidding for a subscription contract must obtain BSI Kitemark certification for Minimized Risk of AMR — a standard requiring that antibiotic manufacturing waste streams stay below Predicted No Effect Concentration thresholds. Companies must either provide proof of certification or submit a delivery plan to achieve it within 12 months of contract start.
Over 25 antibiotic products have been certified, including from Novartis, Sandoz, and Teva. GSK's Worthing facility became the first UK site certified in September 2024. This is the first time any government procurement model has linked market access to environmental manufacturing standards — a recognition that antibiotic resistance is driven not just by clinical misuse but by industrial pollution from the factories that make the drugs.
The EU: A Voucher for a Problem That Needs Cash
The European Union chose a fundamentally different mechanism. On December 11, 2025, the Council and Parliament agreed to include a Transferable Exclusivity Voucher in the landmark Pharma Package — the EU's biggest pharmaceutical reform in over 20 years.
The TEV grants the developer of a qualifying antimicrobial a voucher for 12 months of additional data exclusivity. This voucher can be applied to any centrally authorized product — including a blockbuster oncology drug or biologic — or transferred to another company. The economic logic: a company developing a novel antibiotic can sell the voucher to a company with a product approaching the end of its exclusivity period. The antibiotic developer gets cash; the buyer gets an extra year of monopoly pricing on a high-revenue product.
The guardrails are specific:
- Maximum 5 vouchers EU-wide — scarcity by design
- Blockbuster clause: cannot be used on products with >€490M annual sales
- EU-first filing: marketing authorization application must be submitted to EMA first, or within 180 days of the first global filing
- Supply obligation: failure to supply the antimicrobial in sufficient quantities can result in revocation
- Stewardship and environmental assessment required
The provisional text was published March 6, 2026. Formal adoption is expected mid-2026. But the two-year transition period means the first voucher won't be available until approximately late 2028 or early 2029.
Critics argue the TEV is the most expensive way to incentivize antibiotic development — because the "cost" is borne by patients and health systems who pay monopoly prices longer on other drugs. The OHE has estimated that revenue guarantees and subscription models would achieve the same incentive at lower cost. Others argue the TEV benefits large pharmaceutical companies who can exploit the exclusivity transfer, while doing nothing for the small biotechs that actually develop most new antibiotics and go bankrupt doing so.
The EU's approach addresses the innovation incentive but leaves the access question untouched. There is no EU-wide subscription model, no guaranteed purchase mechanism, no delinked payment. The BEAM Alliance, representing European biotech SMEs, continues to advocate for a complementary subscription approach.
The United States: $6 Billion of Good Intentions, Zero Votes
The PASTEUR Act (H.R. 7352) was reintroduced on February 4, 2026 — its fourth introduction since 2020. It proposes $6 billion for federal subscription contracts of $75-300 million per year per qualifying antimicrobial, for up to 10 years.
The 2026 version includes improvements that address previous criticisms: an objective scoring system to determine contract eligibility and size, an expert advisory committee of infectious disease physicians and resistance experts, and new provisions for outpatient antimicrobial stewardship pilots. Sixty-five bipartisan cosponsors support the bill.
It has never received a floor vote.
In four Congresses across six years, the legislation has been introduced, praised by medical societies, endorsed by IDSA, and referred to committee. Each time, it dies without a vote. The 2026 version has been referred to Energy & Commerce and Budget — the same path its predecessors took to oblivion.
If enacted, PASTEUR would be the largest pull incentive in the world by a factor of roughly 20. Its proposed scale — $300M per year for breakthrough antimicrobials — is the only national figure large enough to plausibly generate the return on investment that would attract major pharmaceutical companies back into antibiotic R&D. The UK's top band of £20M per year is important symbolically but is not large enough alone to recoup the estimated $1.3 billion cost of bringing a new antibiotic to market.
Meanwhile, the US government has announced massive cuts to publicly funded scientific investment in 2025-2026, weakening the "push" incentives (grants, BARDA contracts) that have historically sustained early-stage antibiotic research. BARDA, which has funded critical programs including up to $318M for cefepime-taniborbactam and $93M for Locus Biosciences' LBP-EC01, faces an uncertain future. The floor of the antibiotic innovation ecosystem is falling away while the ceiling remains unbuilt.
The Quiet Movers
Italy: The Surprise Contender
Article 49 of the 2025 Italian budget law opened the national Innovative Medicines Fund to reserve antibiotics targeting WHO priority pathogens, with €100 million per year available. Four to five antibiotics are expected in 2025, with full allocation by 2026-2027. Italy is now the second G7 country to meet its GDP-proportional fair share of a global pull incentive — achieved not through a novel mechanism but through repurposing an existing pharmaceutical reimbursement pathway.
Sweden: Access Without Innovation
Sweden's subscription pilot, running since 2020, guarantees a minimum annual revenue of approximately €356,000 per product for five antibiotics. The government has also purchased an antibiotic manufacturing facility for supply security, and a new 2026-2035 AMR strategy adopted in November 2025 recommended making the subscription permanent with expanded Strama financing. But the Swedish model is access-focused — it ensures availability of existing drugs, not incentivization of new R&D. At €356K, it is too small to influence a development pipeline.
Japan: Strong ROI, Weak Scale
Japan selected cefiderocol as the first drug in its "Antimicrobial Securement Project." Government estimates project a 6:1 return on investment over 10 years and 125:1 over 30 years — perhaps the most compelling economic case any country has made. But initial funding remains below $10M — a supply guarantee, not an innovation incentive.
Canada: Catching Up
Canada's three-year PHAC pilot (FY2024-2027) addresses a startling gap: only 3 of 18 globally available novel antibiotics are registered in Canada. The pilot includes a $3.2M phage therapy component. It is access-focused, not innovation-driving.
Who Is Paying Their Fair Share?
A landmark study published in eClinicalMedicine by Goh, McEnany, Freeman, Newton, Kesselheim, and Outterson quantified the fair share targets: what each G7+EU27 country should contribute, based on GDP, to sustain a viable global pull incentive. The mid-range target across the G7+EU27 is $363 million per year in global revenues per qualifying antimicrobial, sustained for ten years. That would make the drug roughly 230th in a global ranking by revenue — modest by any pharmaceutical standard.
Two of seven G7 nations meet mid-range targets. None meet high-end targets. The country with the largest economy and the highest AMR burden — the United States — has contributed zero dollars to any pull incentive mechanism and has passed no legislation to change this in six years of trying.
The Fundamental Tension
Across these eight experiments, a structural tension emerges that no single model has resolved.
Access models ensure drugs are available. The UK subscription, Sweden's pilot, Japan's securement project, and Canada's pilot all guarantee that hospitals can access critical antibiotics when they need them. They solve the immediate availability crisis — the fact that, for example, only 3 of 18 global antibiotics are registered in Canada. But at their current scale, they cannot generate the returns needed to attract new investment into antibiotic R&D. The OHE has warned that the UK's lower bands (£5-10M per year) "will not be sufficient to stimulate R&D."
Innovation incentives reward development. The EU TEV and the PASTEUR Act both aim to change the fundamental calculation for pharmaceutical companies — to make antibiotic development financially rational again. But the TEV is years from implementation and benefits large companies at the expense of health system costs. The PASTEUR Act would be transformative in scale but remains legislative fiction.
The market needs both. Access without innovation means running out of effective drugs. Innovation without access means developing drugs that never reach the patients who need them. The Goh et al. fair share analysis assumes that 50% of preclinical costs are met through push incentives — grants, BARDA contracts, public-private partnerships. But push incentives in the US are being cut. The entire model rests on a foundation that is eroding.
The estimated cost of bringing a new antibiotic to market is $1.3 billion. The UK's top subscription band pays £20 million per year. Even over the maximum 16-year contract, that is £320 million — roughly a quarter of the development cost. The math requires other countries to pay their share. Most are not.
What April 1 Means
When the UK's expanded subscription contracts begin on April 1, 2026, the world will learn which drugs were selected from the August 2024 tender — which companies met the 17 NICE criteria, which antimicrobials were deemed breakthrough versus important, and how the £100 million annual budget is allocated across the portfolio.
The signal matters beyond the UK. If the model demonstrably sustains companies that would otherwise fail, other countries have a template to follow. If the amounts prove insufficient — if companies still struggle despite subscription payments — the argument shifts toward PASTEUR-scale funding. If the BSI Kitemark requirement proves workable, environmental accountability becomes a replicable procurement condition.
The UK experiment is not just about British healthcare. It is a proof of concept for the world. The Goh et al. analysis calculated that if every G7+EU27 country paid its GDP-proportional fair share, the resulting global pull incentive would amount to roughly $4 billion per qualifying drug — enough to fundamentally change the economics. The UK has built the mechanism. The question is whether anyone follows.
The Center for Global Development estimates the return on investment at 2.5:1 over 10 years for the UK, 6:1 for Japan and the US, and up to 28:1 over 30 years. Every analysis shows that pull incentives pay for themselves many times over. The economics are unambiguous. The politics are not.
More than one million people die each year from drug-resistant infections. That number is projected to reach two million by 2050. The drugs we need most cannot get funded. Eight countries are experimenting with solutions. Two are meeting their targets. The rest are studying the problem, piloting small programs, or debating legislation that never passes.
The global experiment in antibiotic economics is underway. The results so far: necessary, inadequate, and running out of time.